Teva Pharma (TEVA) Reports In-Line Q4 EPS

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.31, in-line with the analyst estimate of $1.31. Revenue for the quarter came in at $5.17 billion versus the consensus estimate of $5.17 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Pembina joins proposed 1M bbl/day Alberta-to-coast pipeline plan
• Freedom Broker Starts Unity Bancorp (UNTY) at Hold